Meta-Analysis of Ferroptosis Inhibitors for Cisplatin-Induced Kidney Injury

58 preclinical studies provide evidence that inhibiting ferroptosis can protect against cisplatin-induced kidney damage. The multilevel meta-analysis synthesizes 265 effect sizes on renal function and ferroptotic biomarkers like GPX4 and GSH. This document, uploaded by Burcu Yuksel in 2026, presents the full systematic review and quantitative results.

Use Cases

• Assessing the renoprotective efficacy of natural and synthetic ferroptosis inhibitors based on pooled effect sizes.
• Analyzing the relationship between antioxidant biomarkers (GPX4, GSH) and renal function outcomes (BUN, SCr).
• Evaluating potential publication bias and small-study effects in preclinical research using PET-PEESE and Trim and Fill methods.
• Identifying dominant moderators of therapeutic effect, such as outcome type, through multilevel meta-regression.

Strengths

• Analysis is based on 58 unique preclinical studies and 265 extracted effect sizes.
• Follows PRISMA 2020 guidelines for systematic review and uses a three-level random-effects model for meta-analysis.
• Examines specific mechanistic biomarkers (GPX4, GSH, MDA, 4-HNE, Fe2+) alongside clinical measures (BUN, SCr).

Limitations

• The dataset is a 231.5 KB DOCX document; the underlying raw data tables are not provided separately.
• The description notes significant residual heterogeneity and potential inflation of pooled estimates due to small-study effects.
• Row count and column-level documentation for any underlying data are unknown.

Provenance

Source

figshare

Collection Method

Systematic review and multilevel meta-analysis conducted according to PRISMA 2020 guidelines, searching PubMed and Web of Science.

Freshness

Last updated 2026-05-04 05:33:14.